Persistence of HIV-1 Transmitted Drug Resistance Mutations | Zendy

Hannah Castro | Zendy; Deenan Pillay | Zendy; Patricia Cane | Zendy; David Asboe | Zendy; Valentina Cambiano | Zendy; Andrew Phillips | Zendy; David Dunn | Zendy; Celia Aitken | Zendy; Daniel Webster | Zendy; David Chadwick | Zendy; Duncan Churchill | Zendy; Duncan A. Clark | Zendy; Simon Collins | Zendy; Valérie Delpech | Zendy; Anna María Geretti | Zendy; David Goldberg | Zendy; Antony Hale | Zendy; Stéphane Hué | Zendy; Steve Kaye | Zendy; Paul Kellam | Zendy; Linda Lazarus | Zendy; Andrew Brown | Zendy; Nicola Mackie | Zendy; Chloe Orkin | Zendy; Philip Rice | Zendy; Erasmus Smit | Zendy; Kate Templeton | Zendy; Peter Tilston | Zendy; C. Y. William Tong | Zendy; Ian Williams | Zendy; Hongyi Zhang | Zendy; Mark Zuckerman | Zendy; Jane Greatorex | Zendy; Adrian Wildfire | Zendy; Siobhan O’Shea | Zendy; Jane Mullen | Zendy; Tamyo Mbisa | Zendy; Alison Cox | Zendy; Richard D. Tandy | Zendy; Tony Hale | Zendy; Tracy Fawcett | Zendy; Mark Hopkins | Zendy; Lynn Ashton | Zendy; Ana Garcia Diaz | Zendy; Jill Shepherd | Zendy; Matthias L. Schmid | Zendy; Brendan Payne | Zendy; Phillip Hay | Zendy; Phillip Rice | Zendy; Mary Paynter | Zendy; David Bibby | Zendy; Stuart A. Kirk | Zendy; Alasdair Maclean | Zendy; Rory Gunson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Persistence of HIV-1 Transmitted Drug Resistance Mutations

Author(s) -

Hannah Castro,

Deenan Pillay,

Patricia Cane,

David Asboe,

Valentina Cambiano,

Andrew Phillips,

David Dunn,

Celia Aitken,

Daniel Webster,

David Chadwick,

Duncan Churchill,

Duncan A. Clark,

Simon Collins,

Valérie Delpech,

Anna María Geretti,

David Goldberg,

Antony Hale,

Stéphane Hué,

Steve Kaye,

Paul Kellam,

Linda Lazarus,

Andrew Brown,

Nicola Mackie,

Chloe Orkin,

Philip Rice,

Erasmus Smit,

Kate Templeton,

Peter Tilston,

C. Y. William Tong,

Ian Williams,

Hongyi Zhang,

Mark Zuckerman,

Jane Greatorex,

Adrian Wildfire,

Siobhan O’Shea,

Jane Mullen,

Tamyo Mbisa,

Alison Cox,

Richard D. Tandy,

Tony Hale,

Tracy Fawcett,

Mark Hopkins,

Lynn Ashton,

Ana Garcia Diaz,

Jill Shepherd,

Matthias L. Schmid,

Brendan Payne,

Phillip Hay,

Phillip Rice,

Mary Paynter,

David Bibby,

Stuart A. Kirk,

Alasdair Maclean,

Rory Gunson

Publication year - 2013

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jit345

Subject(s) - censoring (clinical trials) , persistence (discontinuity) , virology , drug resistance , mutation rate , biology , mutation , human immunodeficiency virus (hiv) , genetics , drug , hiv drug resistance , immunology , medicine , viral load , pharmacology , gene , antiretroviral therapy , pathology , geotechnical engineering , engineering

There are few data on the persistence of individual human immunodeficiency virus type 1 (HIV-1) transmitted drug resistance (TDR) mutations in the absence of selective drug pressure. We studied 313 patients in whom TDR mutations were detected at their first resistance test and who had a subsequent test performed while ART-naive. The rate at which mutations became undetectable was estimated using exponential regression accounting for interval censoring. Most thymidine analogue mutations (TAMs) and T215 revertants (but not T215F/Y) were found to be highly stable, with NNRTI and PI mutations being relatively less persistent. Our estimates are important for informing HIV transmission models.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research